Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L; ONYX study group. Eriksson BI, et al. Among authors: meems l. J Thromb Haemost. 2007 Aug;5(8):1660-5. doi: 10.1111/j.1538-7836.2007.02644.x. J Thromb Haemost. 2007. PMID: 17663737 Free article. Clinical Trial.
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP. Eriksson BI, et al. Among authors: meems l. J Thromb Haemost. 2010 Apr;8(4):714-21. doi: 10.1111/j.1538-7836.2010.03748.x. Epub 2010 Jan 17. J Thromb Haemost. 2010. PMID: 20088935 Free article. Clinical Trial.
Circulating ECM proteins decorin and alpha-L-iduronidase differentiate ATTRwt-CM from ATTRwt-negative HFpEF/HFmrEF.
Tubben A, Markousis-Mavrogenis G, Meems LMG, van Essen BJ, Baumhove L, Berends M, Tingen HSA, Bijzet J, Hazenberg BPC, Voors AA, van Veldhuisen DJ, Slart RHJA, Nienhuis HLA, van der Meer P. Tubben A, et al. Among authors: meems lmg. Cardiovasc Res. 2024 Nov 25;120(14):1727-1736. doi: 10.1093/cvr/cvae189. Cardiovasc Res. 2024. PMID: 39288026 Free PMC article.
Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study.
Tubben A, Tingen HSA, Prakken NHJ, van Empel VPM, Gorter TM, Meems LMG, Manintveld OC, Rienstra M, Tieleman RG, Glaudemans AWJM, van Veldhuisen DJ, Slart RHJA, Nienhuis HLA, van der Meer P. Tubben A, et al. Among authors: meems lmg. Eur J Heart Fail. 2024 Mar;26(3):695-698. doi: 10.1002/ejhf.3186. Epub 2024 Mar 4. Eur J Heart Fail. 2024. PMID: 38439596 No abstract available.
The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF.
Withaar C, Meems LMG, Nollet EE, Schouten EM, Schroeder MA, Knudsen LB, Niss K, Madsen CT, Hoegl A, Mazzoni G, van der Velden J, Lam CSP, Silljé HHW, de Boer RA. Withaar C, et al. Among authors: meems lmg. JACC Basic Transl Sci. 2023 Jul 26;8(10):1298-1314. doi: 10.1016/j.jacbts.2023.05.012. eCollection 2023 Oct. JACC Basic Transl Sci. 2023. PMID: 38094687 Free PMC article.
The 'peptide for life' initiative in the emergency department study.
Bayes-Genis A, Krljanac G, Zdravković M, Ašanin M, Stojšić-Milosavljević A, Radovanović S, Kovačević TP, Selaković A, Milinković I, Polovina M, Glavaš D, Srbinovska E, Bulatović N, Miličić D, Čikeš M, Babić Z, Šikić J, Kušljugić Z, Hudić LD, Arfsten H, Meems LMG, Metra M, Rosano G, Seferović PM; Young Investigators of the Peptide for Life Initiative. Bayes-Genis A, et al. Among authors: meems lmg. ESC Heart Fail. 2024 Apr;11(2):672-680. doi: 10.1002/ehf2.14625. Epub 2023 Dec 13. ESC Heart Fail. 2024. PMID: 38093494 Free PMC article.
51 results